特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
965904

呼吸器ウイルスワクチンの市場規模:業界分析、シェア、成長、動向、および予測(2020年~2030年)

Respiratory Virus Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

出版日: | 発行: Transparency Market Research | ページ情報: 英文 193 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
呼吸器ウイルスワクチンの市場規模:業界分析、シェア、成長、動向、および予測(2020年~2030年)
出版日: 2020年08月17日
発行: Transparency Market Research
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、世界の呼吸器ウイルスワクチン市場について調査しており、市場機会、成長および抑制要因、COVID-19の影響、タイプ・投与経路・適応症・年齢層・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
    • 成長要因
    • 抑制要因
    • 市場機会
  • 市場分析と予測(2018-2030)

第5章 市場の見通し

  • 主要な業界イベント(合併、買収、協業、承認など)
  • 主要国における疾病有病率と発生率
  • パイプライン分析
  • COVID-19パンデミックによる業界への影響(バリューチェーンおよび短期/中期/長期の影響)価格分析

第6章 市場分析:タイプ別

  • イントロダクションと定義
  • 売上予測(2018-2030)
    • 不活化ワクチン
    • フルミストワクチン
    • 組換えワクチン
  • 市場の魅力分析

第7章 市場分析:投与経路別

  • イントロダクションと定義
  • 売上予測(2018-2030)
    • 筋肉内
    • 鼻腔内
    • 皮下
  • 市場の魅力分析

第8章 市場分析:適応症別

  • 売上予測(2018-2030)
    • インフルエンザ
    • はしか、おたふく風邪、風疹
    • COVID-19
    • その他
  • 市場の魅力分析

第9章 市場分析:年齢層別

  • 売上予測(2018-2030)
    • 小児
    • 大人
  • 市場の魅力分析

第10章 市場分析:エンドユーザー別

  • 売上予測(2018-2030)
    • 診療所
    • 病院
    • クリニック
    • 薬局/店舗
    • その他
  • 市場の魅力分析

第11章 市場分析:地域別

  • 概要
  • 売上予測(2018-2030)
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析

第12章 北米

  • 概要
  • タイプ別(2018-2030)
  • 投与経路別(2018-2030)
  • 適応症別(2018-2030)
  • 年齢層別(2018-2030)
  • エンドユーザー別(2018-2030)
  • 国別(2018-2030)
    • 米国
    • カナダ
  • 市場の魅力分析

第13章 欧州

第14章 アジア太平洋地域

第15章 ラテンアメリカ

第16章 中東およびアフリカ

第17章 競合情勢

  • 市場企業:競合マトリックス(企業の階層と規模別)
  • 世界の市況分析:企業別(2019)
  • 企業プロファイル
    • CSL Limited
    • Sanofi
    • AstraZeneca
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Serum Institute of India Pvt. Ltd.
    • Bharat Biotech
    • Sinovac Biotech Ltd.
図表

List of Tables:

  • Table 01 Pipeline Analysis (1/4)
  • Table 02 Pipeline Analysis (2/4)
  • Table 03 Pipeline Analysis (3/4)
  • Table 04 Pipeline Analysis (4/4)
  • Table 05 Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.) (1/3)
  • Table 06 Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.) (2/3)
  • Table 07 Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.) (3/3)
  • Table 08 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018-2030
  • Table 09 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 10 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 11 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018-2030
  • Table 12 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018-2030
  • Table 13 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Region, 2018-2030
  • Table 14 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country, 2018-2030
  • Table 15 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018-2030
  • Table 16 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 17 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 18 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018-2030
  • Table 19 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018-2030
  • Table 20 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 21 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018-2030
  • Table 22 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 23 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 24 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018-2030
  • Table 25 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018-2030
  • Table 26 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 27 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018-2030
  • Table 28 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 29 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 30 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018-2030
  • Table 31 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018-2030
  • Table 32 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 33 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018-2030
  • Table 34 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 35 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 36 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018-2030
  • Table 37 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018-2030
  • Table 38 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 39 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018-2030
  • Table 40 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 41 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 42 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018-2030
  • Table 43 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018-2030

List of Figures:

  • Figure 01 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030
  • Figure 02 Global Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030
  • Figure 03 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030
  • Figure 04 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Inactivated/Killed Vaccines, 2018-2030
  • Figure 05 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Live-attenuated Vaccines, 2018-2030
  • Figure 06 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Recombinant vaccines, 2018-2030
  • Figure 07 Global Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 08 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 09 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Intramuscular, 2018-2030
  • Figure 10 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Intranasal, 2018-2030
  • Figure 11 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Subcutaneous, 2018-2030
  • Figure 12 Global Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 13 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 14 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Influenza, 2018-2030
  • Figure 15 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Measles, Mumps & Rubella, 2018-2030
  • Figure 16 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Coronavirus Disease (COVID-19), 2018-2030
  • Figure 17 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2018-2030
  • Figure 18 Global Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030
  • Figure 19 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030
  • Figure 20 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Pediatric, 2018-2030
  • Figure 21 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Adult, 2018-2030
  • Figure 22 Global Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030
  • Figure 23 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030
  • Figure 24 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Physician Offices, 2018-2030
  • Figure 25 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2018-2030
  • Figure 26 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2018-2030
  • Figure 27 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Pharmacy/Store, 2018-2030
  • Figure 28 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2018-2030
  • Figure 29 Global Respiratory Virus Vaccines Market Value Share Analysis, by Region, 2019 and 2030
  • Figure 30 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Region, 2020-2030
  • Figure 31 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030
  • Figure 32 North America Respiratory Virus Vaccines Market Value Share Analysis, by Country, 2019 and 2030
  • Figure 33 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by Country, 2020-2030
  • Figure 34 North America Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030
  • Figure 35 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030
  • Figure 36 North America Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 37 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 38 North America Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 39 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 40 North America Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030
  • Figure 41 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030
  • Figure 42 North America Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030
  • Figure 43 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030
  • Figure 44 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030
  • Figure 45 Europe Respiratory Virus Vaccines Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
  • Figure 46 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by Country, 2020-2030
  • Figure 47 Europe Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030
  • Figure 48 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030
  • Figure 49 Europe Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 50 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 51 Europe Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 52 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 53 Europe Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030
  • Figure 54 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030
  • Figure 55 Europe Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030
  • Figure 56 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030
  • Figure 57 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030
  • Figure 58 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
  • Figure 59 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
  • Figure 60 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030
  • Figure 61 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030
  • Figure 62 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 63 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 64 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 65 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 66 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030
  • Figure 67 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030
  • Figure 68 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030
  • Figure 69 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030
  • Figure 70 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030
  • Figure 71 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
  • Figure 72 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
  • Figure 73 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030
  • Figure 74 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030
  • Figure 75 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 76 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 77 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 78 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 79 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030
  • Figure 80 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030
  • Figure 81 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030
  • Figure 82 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030
  • Figure 83 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030
  • Figure 84 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
  • Figure 85 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
  • Figure 86 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030
  • Figure 87 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030
  • Figure 88 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 89 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 90 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 91 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 92 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030
  • Figure 93 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030
  • Figure 94 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030
  • Figure 95 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030
目次
Product Code: TMRGL78499

Title:
Respiratory Virus Vaccines Market (Type: Inactivated/Killed Vaccines, Live-attenuated Vaccines, and Recombinant Vaccines; Route of Administration: Intramuscular, Intranasal, and Subcutaneous; Indication: Influenza, Measles, Mumps & Rubella, Coronavirus Disease [COVID-19], and Others; Age Group: Pediatric and Adults; and End User: Physician's Office, Hospitals, Clinics, and Pharmacies/Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030.

Respiratory Virus Vaccines Market - Scope of the Report

TMR's report on the global respiratory virus vaccines market studies the past as well as current growth trends and opportunities to gain valuable insights for the market during the forecast period from 2020 to 2030. The report provides the revenue of the global respiratory virus vaccines market for period from 2018 to 2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR %) for the global respiratory virus vaccines market for the same period.

The report has been prepared after extensive research. Primary research involves bulk of research efforts, wherein analysts conducted interviews with market leaders and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global respiratory virus vaccines market.

Secondary research also includes Internet sources and statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of top-down and bottom-up approaches to study various phenomena in the global respiratory virus vaccines market.

The report includes an elaborate executive summary, along with a snapshot of the growth pattern of various market segments included in the scope of the study. Furthermore, the report sheds light on the changing competition dynamics in the global respiratory virus vaccines market. These indices serve as valuable tools for existing market players as well as new players interested in entering the global respiratory virus vaccines market. The next section of the report highlights the USPs, which include pipeline analysis, disease prevalence & incidence rate globally with key countries, key industry events (mergers, acquisitions, collaborations, approvals, etc.) and COVID-19 pandemic impact on industry (value chain and short-/mid-/ long-term impact).

The report delves into the competitive landscape of the global respiratory virus vaccines market. Key players operating in the global respiratory virus vaccines market have been identified and each one of them has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players operating in the global respiratory virus vaccines market profiled in this report.

Key Questions Answered in Respiratory Virus Vaccines Market Report

What are the major drivers, restraints, and opportunities in the global respiratory virus vaccines market?

What is the revenue share projection of key segments of the global respiratory virus vaccines market during the forecast period?

Which segment is likely to lead the global respiratory virus vaccines market in terms of revenue between 2020 and 2030?

How mergers & acquisitions among players are widening the scope of the global respiratory virus vaccines market?

What is the market position of different companies operating in the global respiratory virus vaccines market?

Respiratory Virus Vaccines Market - Research Objectives and Research Approach

The comprehensive report on the global respiratory virus vaccines market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of objectives of this study and healthcare compliances laid down by accredited agencies in the purview of research in the global respiratory virus vaccines market. It is followed by market introduction, market dynamics, and an overview of the global respiratory virus vaccines market, which includes TMR's analysis of market drivers, restraints, and trends pertaining to the global respiratory virus vaccines market. Furthermore, Y-o-Y growth analysis with elaborated insights has been provided in order to understand the Y-o-Y growth trend of the global respiratory virus vaccines market. The next section of the global respiratory virus vaccines report highlights the USPs, which include pipeline analysis, disease prevalence & incidence rate globally with key countries, key industry events (mergers, acquisitions, collaborations, approvals, etc.) and COVID-19 pandemic impact on industry (value chain and short-/mid-/long-term impact).

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into smaller ones. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.

The report segments the global respiratory virus vaccines market in terms of type, route of administration, indication, age group, end user, and region. Key segments under each criterion have been studied at length and the market share for each segment by the end of 2030 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investments in the global respiratory virus vaccines market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Respiratory Virus Vaccines Market

4. Market Overview

  • 4.1. Introduction
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Respiratory Virus Vaccines Market Analysis and Forecast, 2018-2030

5. Market Outlook

  • 5.1. Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.)
  • 5.2. Disease Prevalence & Incidence Rate globally with key countries
  • 5.3. Pipeline Analysis
  • 5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short-/Mid-/Long-term Impact) Pricing Analysis

6. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Global Respiratory Virus Vaccines Market Value Forecast, by Type, 2018-2030
    • 6.2.1. Inactivated/Killed Vaccines
    • 6.2.2. Live-attenuated Vaccines
    • 6.2.3. Recombinant vaccines
  • 6.3. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Type

7. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Global Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018-2030
    • 7.2.1. Intramuscular
    • 7.2.2. Intranasal
    • 7.2.3. Subcutaneous
  • 7.3. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration

8. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication

  • 8.1. Global Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018-2030
    • 8.1.1. Influenza
    • 8.1.2. Measles, Mumps & Rubella
    • 8.1.3. Coronavirus Disease (COVID-19)
    • 8.1.4. Others
  • 8.2. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication

9. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group

  • 9.1. Global Respiratory Virus Vaccines Market Value Forecast, by Age Group, 2018-2030
    • 9.1.1. Pediatric
    • 9.1.2. Adults
  • 9.2. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group

10. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user

  • 10.1. Global Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018-2030
    • 10.1.1. Physician's Office
    • 10.1.2. Hospitals
    • 10.1.3. Clinics
    • 10.1.4. Pharmacy/Store
    • 10.1.5. Others
  • 10.2. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user

11. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Region

  • 11.1. Introduction
  • 11.2. Global Respiratory Virus Vaccines Market Value Forecast, by Region, 2018-2030
    • 11.2.1. North America
    • 11.2.2. Europe
    • 11.2.3. Asia Pacific
    • 11.2.4. Latin America
    • 11.2.5. Middle East & Africa
  • 11.3. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Region

12. North America Respiratory Virus Vaccines Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. North America Respiratory Virus Vaccines Market Value Forecast, by Type, 2018-2030
    • 12.2.1. Inactivated/Killed Vaccines
    • 12.2.2. Live-attenuated Vaccines
    • 12.2.3. Recombinant vaccines
  • 12.3. North America Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018-2030
    • 12.3.1. Intramuscular
    • 12.3.2. Intranasal
    • 12.3.3. Subcutaneous
  • 12.4. North America Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018-2030
    • 12.4.1. Influenza
    • 12.4.2. Measles, Mumps & Rubella
    • 12.4.3. Coronavirus Disease (COVID-19)
    • 12.4.4. Others
  • 12.5. North America Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018-2030
    • 12.5.1. Pediatric
    • 12.5.2. Adults
  • 12.6. North America Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018-2030
    • 12.6.1. Physician Offices
    • 12.6.2. Hospitals
    • 12.6.3. Clinics
    • 12.6.4. Pharmacy/Store
    • 12.6.5. Others
  • 12.7. North America Respiratory Virus Vaccines Market Value Forecast, by Country, 2018-2030
    • 12.7.1. U.S.
    • 12.7.2. Canada
  • 12.8. North America Respiratory Virus Vaccines Market Attractiveness Analysis
    • 12.8.1. By Type
    • 12.8.2. By Route of Administration
    • 12.8.3. By Indication
    • 12.8.4. By Age Group
    • 12.8.5. By End-user
    • 12.8.6. By Country

13. Europe Respiratory Virus Vaccines Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Europe Respiratory Virus Vaccines Market Value Forecast, by Type, 2018-2030
    • 13.2.1. Inactivated/Killed Vaccines
    • 13.2.2. Live-attenuated Vaccines
    • 13.2.3. Recombinant vaccines
  • 13.3. Europe Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018-2030
    • 13.3.1. Intramuscular
    • 13.3.2. Intranasal
    • 13.3.3. Subcutaneous
  • 13.4. Europe Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018-2030
    • 13.4.1. Influenza
    • 13.4.2. Measles, Mumps & Rubella
    • 13.4.3. Coronavirus Disease (COVID-19)
    • 13.4.4. Others
  • 13.5. Europe Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018-2030
    • 13.5.1. Pediatric
    • 13.5.2. Adults
  • 13.6. Europe Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018-2030
    • 13.6.1. Physician Offices
    • 13.6.2. Hospitals
    • 13.6.3. Clinics
    • 13.6.4. Pharmacy/Store
    • 13.6.5. Others
  • 13.7. Europe Respiratory Virus Vaccines Market Value Forecast, by Country/Sub-region, 2018-2030
    • 13.7.1. Germany
    • 13.7.2. U.K.
    • 13.7.3. France
    • 13.7.4. Spain
    • 13.7.5. Italy
    • 13.7.6. Rest of Europe
  • 13.8. Europe Respiratory Virus Vaccines Market Attractiveness Analysis
    • 13.8.1. By Type
    • 13.8.2. By Route of Administration
    • 13.8.3. By Indication
    • 13.8.4. By Age Group
    • 13.8.5. By End-user
    • 13.8.6. By Country/Sub-region

14. Asia Pacific Respiratory Virus Vaccines Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Type, 2018-2030
    • 14.2.1. Inactivated/Killed Vaccines
    • 14.2.2. Live-attenuated Vaccines
    • 14.2.3. Recombinant vaccines
  • 14.3. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018-2030
    • 14.3.1. Intramuscular
    • 14.3.2. Intranasal
    • 14.3.3. Subcutaneous
  • 14.4. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018-2030
    • 14.4.1. Influenza
    • 14.4.2. Measles, Mumps & Rubella
    • 14.4.3. Coronavirus Disease (COVID-19)
    • 14.4.4. Others
  • 14.5. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018-2030
    • 14.5.1. Pediatric
    • 14.5.2. Adults
  • 14.6. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018-2030
    • 14.6.1. Physician Offices
    • 14.6.2. Hospitals
    • 14.6.3. Clinics
    • 14.6.4. Pharmacy/Store
    • 14.6.5. Others
  • 14.7. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Country/Sub-region, 2018-2030
    • 14.7.1. Japan
    • 14.7.2. China
    • 14.7.3. India
    • 14.7.4. Australia & New Zealand
    • 14.7.5. Rest of Asia Pacific
  • 14.8. Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis
    • 14.8.1. By Type
    • 14.8.2. By Route of Administration
    • 14.8.3. By Indication
    • 14.8.4. By Age Group
    • 14.8.5. By End-user
    • 14.8.6. By Country/Sub-region

15. Latin America Respiratory Virus Vaccines Market Analysis and Forecast

  • 15.1. Introduction
  • 15.2. Latin America Respiratory Virus Vaccines Market Value Forecast, by Type, 2018-2030
    • 15.2.1. Inactivated/Killed Vaccines
    • 15.2.2. Live-attenuated Vaccines
    • 15.2.3. Recombinant vaccines
  • 15.3. Latin America Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018-2030
    • 15.3.1. Intramuscular
    • 15.3.2. Intranasal
    • 15.3.3. Subcutaneous
  • 15.4. Latin America Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018-2030
    • 15.4.1. Influenza
    • 15.4.2. Measles, Mumps & Rubella
    • 15.4.3. Coronavirus Disease (COVID-19)
    • 15.4.4. Others
  • 15.5. Latin America Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018-2030
    • 15.5.1. Pediatric
    • 15.5.2. Adults
  • 15.6. Latin America Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018-2030
    • 15.6.1. Physician Offices
    • 15.6.2. Hospitals
    • 15.6.3. Clinics
    • 15.6.4. Pharmacy/Store
    • 15.6.5. Others
  • 15.7. Latin America Respiratory Virus Vaccines Market Value Forecast, by Country/Sub-region, 2018-2030
    • 15.7.1. Brazil
    • 15.7.2. Mexico
    • 15.7.3. Rest of Latin America
  • 15.8. Latin America Respiratory Virus Vaccines Market Attractiveness Analysis
    • 15.8.1. By Type
    • 15.8.2. By Route of Administration
    • 15.8.3. By Indication
    • 15.8.4. By Age Group
    • 15.8.5. By End-user
    • 15.8.6. By Country/Sub-region

16. Middle East & Africa Respiratory Virus Vaccines Market Analysis and Forecast

  • 16.1. Introduction
  • 16.2. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Type, 2018-2030
    • 16.2.1. Inactivated/Killed Vaccines
    • 16.2.2. Live-attenuated Vaccines
    • 16.2.3. Recombinant vaccines
  • 16.3. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Route of Administration , 2018-2030
    • 16.3.1. Intramuscular
    • 16.3.2. Intranasal
    • 16.3.3. Subcutaneous
  • 16.4. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018-2030
    • 16.4.1. Influenza
    • 16.4.2. Measles, Mumps & Rubella
    • 16.4.3. Coronavirus Disease (COVID-19)
    • 16.4.4. Others
  • 16.5. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018-2030
    • 16.5.1. Pediatric
    • 16.5.2. Adults
  • 16.6. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018-2030
    • 16.6.1. Physician Offices
    • 16.6.2. Hospitals
    • 16.6.3. Clinics
    • 16.6.4. Pharmacy/Store
    • 16.6.5. Others
  • 16.7. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Country/Sub-region, 2018-2030
    • 16.7.1. GCC Countries
    • 16.7.2. South Africa
    • 16.7.3. Rest of Middle East & Africa
  • 16.8. Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis
    • 16.8.1. By Type
    • 16.8.2. By Route of Administration
    • 16.8.3. By Indication
    • 16.8.4. By Age Group
    • 16.8.5. By End-user
    • 16.8.6. By Country/Sub-region

17. Competition Landscape

  • 17.1. Market Player - Competition Matrix (by tier and size of companies)
  • 17.2. Global Respiratory Virus Vaccines Market Position Analysis, by Company, 2019
  • 17.3. Company Profiles
    • 17.3.1. CSL Limited
      • 17.3.1.1. Company Description
      • 17.3.1.2. Business Overview
      • 17.3.1.3. Financial Overview
      • 17.3.1.4. Strategic Overview
      • 17.3.1.5. SWOT Analysis
    • 17.3.2. Sanofi
      • 17.3.2.1. Company Description
      • 17.3.2.2. Business Overview
      • 17.3.2.3. Financial Overview
      • 17.3.2.4. Strategic Overview
      • 17.3.2.5. SWOT Analysis
    • 17.3.3. AstraZeneca
      • 17.3.3.1. Company Description
      • 17.3.3.2. Business Overview
      • 17.3.3.3. Financial Overview
      • 17.3.3.4. Strategic Overview
      • 17.3.3.5. SWOT Analysis
    • 17.3.4. Merck & Co., Inc.
      • 17.3.4.1. Company Description
      • 17.3.4.2. Business Overview
      • 17.3.4.3. Strategic Overview
      • 17.3.4.4. Financial Overview
      • 17.3.4.5. SWOT Analysis
    • 17.3.5. GlaxoSmithKline plc
      • 17.3.5.1. Company Description
      • 17.3.5.2. Business Overview
      • 17.3.5.3. Strategic Overview
      • 17.3.5.4. Financial Overview
      • 17.3.5.5. SWOT Analysis
    • 17.3.6. Serum Institute of India Pvt. Ltd.
      • 17.3.6.1. Company Description
      • 17.3.6.2. Business Overview
      • 17.3.6.3. Financial Overview
      • 17.3.6.4. Strategic Overview
      • 17.3.6.5. SWOT Analysis
    • 17.3.7. Bharat Biotech
      • 17.3.7.1. Company Description
      • 17.3.7.2. Business Overview
      • 17.3.7.3. Financial Overview
      • 17.3.7.4. Strategic Overview
      • 17.3.7.5. SWOT Analysis
    • 17.3.8. Sinovac Biotech Ltd.
      • 17.3.8.1. Company Description
      • 17.3.8.2. Business Overview
      • 17.3.8.3. Financial Overview
      • 17.3.8.4. Strategic Overview
      • 17.3.8.5. SWOT Analysis
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.